Melrilimab clinical trials
Also written GSK3772847.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses melrilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GSK3772847
- 2
Studies by the year they started
4 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
GlaxoSmithKline (3) · Janssen Research & Development, LLC (1)
Studies
Open first, then newest update. How each study uses melrilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy ParticipantsCompletedPhase 1GlaxoSmithKlineNCT04366349Written as melrilimab (GSK3772847) 70 milligram (mg)
- A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic DermatitisCompletedPhase 1Janssen Research & Development, LLCNCT02345928Written as Part 1: CNTO 7160
- Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)TerminatedPhase 2GlaxoSmithKlineNCT03393806Written as GSK3772847
- Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe AsthmaCompletedPhase 2GlaxoSmithKlineNCT03207243Written as GSK3772847
Codes
What other systems call melrilimab · ClinicalTrials.gg INT002020
- MeSH (NLM) C000728059melrilimabOne source NLM
- UNII (FDA) 26C72EGQ3GMELRILIMABConfirmed FDA, NLM
- NCI Thesaurus C175124MelrilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000728059 | melrilimab | One source NLM |
| UNII (FDA) | 26C72EGQ3G | MELRILIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C175124 | Melrilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.